Skip to main content
. 2017 Sep 8;1(20):1760–1772. doi: 10.1182/bloodadvances.2017004960

Figure 4.

Figure 4.

Microarray expression analyses reveal the low mitochondrial respiration, low glycolysis, and delayed cell-cycle progression of tail-derived hT-ALL. Microarrays of thorax- or tail-derived hT-ALL were performed in 3 hT-ALL (#1, #3, #10). (A) Gene set enrichment analysis (GSEA) (Affymetrix arrays) for hallmark oxidative phosphorylation in thorax- or tail-derived hT-ALL. (B, left) OCR measured in thorax- and tail-derived hT-ALL#1 using XFp Analyzer (Seahorse Bioscience). (B, right) Basal respiration (OCR) for 4 experiments. (C, left) Comparison between MFI of MTG from thorax- and tail-derived hT-ALL (4 hT-ALL, 14 mice). (C, right) Comparison between MFI of TMRE from thorax-derived and tail-derived hT-ALL (2hT-ALL, 10 mice). (D) GSEA for Hallmark glycolysis in thorax-derived or tail-derived hT-ALL. (E, left) ECAR measured in thorax-and tail-derived hT-ALL#1 using XFp Analyzer. (E, right) Glycolytic capacity (ECAR) for 2 hT-ALL. (F) Comparison between G6PD activity in thorax- and tail-derived hT-ALL#3 for 3 mice. (G) GSEA for hallmark E2F targets in thorax- or tail-derived hT-ALL. (H, left) Leukemic cells in G0, G1, S, and G2/M phases across hT-ALL samples (6 hT-ALL, 20 mice). (H, right) Ki67-Hoechst cell-cycle analysis by flow cytometry for thorax- or tail-derived hT-ALL#1. Statistics are calculated according to nonparametric Wilcoxon or Mann-Whitney U test (**P < .01; ***P < .001; ****P < .0001). FDR, false discovery rate.